Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis

a prospective study

Giovanni Ferrara, Monica Losi, Roberto D'Amico, Pietro Roversi, Roberto Piro, Marisa Meacci, Barbara Meccugni, Ilaria Marchetti Dori, Alessandro Andreani, Barbara Maria Bergamini, Cristina Mussini, Fabio Rumpianesi, Leonardo M. Fabbri, Luca Richeldi

Research output: Contribution to journalArticle

434 Citations (Scopus)

Abstract

Background: Two commercial blood assays for the diagnosis of latent tuberculosis infection-T-SPOT.TB and QuantiFERON-TB Gold-have been separately compared with the tuberculin skin test. Our aim was to compare the efficacy of all three tests in the same population sample. Methods: We did a prospective study in 393 consecutively enrolled patients who were tested simultaneously with T-SPOT.TB and QuantiFERON-TB Gold because of suspected latent or active tuberculosis. 318 patients also had results available for a tuberculin skin test. Findings: Overall agreement with the skin test was similar (T-SPOT.TB κ=0·508, QuantiFERON-TB Gold κ=0·460), but fewer BCG-vaccinated individuals were identified as positive by the two blood assays than by the tuberculin skin test (p=0·003 for T-SPOT.TB and p

Original languageEnglish
Pages (from-to)1328-1334
Number of pages7
JournalLancet
Volume367
Issue number9519
DOIs
Publication statusPublished - Apr 22 2006

Fingerprint

Hematologic Tests
Skin Tests
Mycobacterium tuberculosis
Tuberculin Test
Gold
Prospective Studies
Infection
Latent Tuberculosis
Mycobacterium bovis
Tuberculosis
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis : a prospective study. / Ferrara, Giovanni; Losi, Monica; D'Amico, Roberto; Roversi, Pietro; Piro, Roberto; Meacci, Marisa; Meccugni, Barbara; Dori, Ilaria Marchetti; Andreani, Alessandro; Bergamini, Barbara Maria; Mussini, Cristina; Rumpianesi, Fabio; Fabbri, Leonardo M.; Richeldi, Luca.

In: Lancet, Vol. 367, No. 9519, 22.04.2006, p. 1328-1334.

Research output: Contribution to journalArticle

Ferrara, G, Losi, M, D'Amico, R, Roversi, P, Piro, R, Meacci, M, Meccugni, B, Dori, IM, Andreani, A, Bergamini, BM, Mussini, C, Rumpianesi, F, Fabbri, LM & Richeldi, L 2006, 'Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study', Lancet, vol. 367, no. 9519, pp. 1328-1334. https://doi.org/10.1016/S0140-6736(06)68579-6
Ferrara, Giovanni ; Losi, Monica ; D'Amico, Roberto ; Roversi, Pietro ; Piro, Roberto ; Meacci, Marisa ; Meccugni, Barbara ; Dori, Ilaria Marchetti ; Andreani, Alessandro ; Bergamini, Barbara Maria ; Mussini, Cristina ; Rumpianesi, Fabio ; Fabbri, Leonardo M. ; Richeldi, Luca. / Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis : a prospective study. In: Lancet. 2006 ; Vol. 367, No. 9519. pp. 1328-1334.
@article{c135ba604acc467ba480e947d6fe9a61,
title = "Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study",
abstract = "Background: Two commercial blood assays for the diagnosis of latent tuberculosis infection-T-SPOT.TB and QuantiFERON-TB Gold-have been separately compared with the tuberculin skin test. Our aim was to compare the efficacy of all three tests in the same population sample. Methods: We did a prospective study in 393 consecutively enrolled patients who were tested simultaneously with T-SPOT.TB and QuantiFERON-TB Gold because of suspected latent or active tuberculosis. 318 patients also had results available for a tuberculin skin test. Findings: Overall agreement with the skin test was similar (T-SPOT.TB κ=0·508, QuantiFERON-TB Gold κ=0·460), but fewer BCG-vaccinated individuals were identified as positive by the two blood assays than by the tuberculin skin test (p=0·003 for T-SPOT.TB and p",
author = "Giovanni Ferrara and Monica Losi and Roberto D'Amico and Pietro Roversi and Roberto Piro and Marisa Meacci and Barbara Meccugni and Dori, {Ilaria Marchetti} and Alessandro Andreani and Bergamini, {Barbara Maria} and Cristina Mussini and Fabio Rumpianesi and Fabbri, {Leonardo M.} and Luca Richeldi",
year = "2006",
month = "4",
day = "22",
doi = "10.1016/S0140-6736(06)68579-6",
language = "English",
volume = "367",
pages = "1328--1334",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9519",

}

TY - JOUR

T1 - Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis

T2 - a prospective study

AU - Ferrara, Giovanni

AU - Losi, Monica

AU - D'Amico, Roberto

AU - Roversi, Pietro

AU - Piro, Roberto

AU - Meacci, Marisa

AU - Meccugni, Barbara

AU - Dori, Ilaria Marchetti

AU - Andreani, Alessandro

AU - Bergamini, Barbara Maria

AU - Mussini, Cristina

AU - Rumpianesi, Fabio

AU - Fabbri, Leonardo M.

AU - Richeldi, Luca

PY - 2006/4/22

Y1 - 2006/4/22

N2 - Background: Two commercial blood assays for the diagnosis of latent tuberculosis infection-T-SPOT.TB and QuantiFERON-TB Gold-have been separately compared with the tuberculin skin test. Our aim was to compare the efficacy of all three tests in the same population sample. Methods: We did a prospective study in 393 consecutively enrolled patients who were tested simultaneously with T-SPOT.TB and QuantiFERON-TB Gold because of suspected latent or active tuberculosis. 318 patients also had results available for a tuberculin skin test. Findings: Overall agreement with the skin test was similar (T-SPOT.TB κ=0·508, QuantiFERON-TB Gold κ=0·460), but fewer BCG-vaccinated individuals were identified as positive by the two blood assays than by the tuberculin skin test (p=0·003 for T-SPOT.TB and p

AB - Background: Two commercial blood assays for the diagnosis of latent tuberculosis infection-T-SPOT.TB and QuantiFERON-TB Gold-have been separately compared with the tuberculin skin test. Our aim was to compare the efficacy of all three tests in the same population sample. Methods: We did a prospective study in 393 consecutively enrolled patients who were tested simultaneously with T-SPOT.TB and QuantiFERON-TB Gold because of suspected latent or active tuberculosis. 318 patients also had results available for a tuberculin skin test. Findings: Overall agreement with the skin test was similar (T-SPOT.TB κ=0·508, QuantiFERON-TB Gold κ=0·460), but fewer BCG-vaccinated individuals were identified as positive by the two blood assays than by the tuberculin skin test (p=0·003 for T-SPOT.TB and p

UR - http://www.scopus.com/inward/record.url?scp=33646026410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646026410&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(06)68579-6

DO - 10.1016/S0140-6736(06)68579-6

M3 - Article

VL - 367

SP - 1328

EP - 1334

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9519

ER -